The goal of this study was divided into three parts: first, to investigate whether MET is the target of CBL in lung cancer; second, to investigate whether CBL Mts affect the sensitivity of cancer cells to specific cancer therapeutics; and third, to study the response of MET inhibitor SU11274 when treated in A549 CBL isogenic cells. This evidence concerns the gene MET and cancer.